A Prospective non-interventional study (NIS) of trastuzumab deRuxtecan (T-DXd) for adult patients with advanced HER2-pOsitive gaStric or gastroesoPhageal junction (GEJ) adEnocarcinoma who have Received a prIor Trastuzumab-based regimen, accompanied by a disease registrY of patients treated with conventional therapies in a real-world setting in Europe (PROSPERITY).

Study type

• Study type:
  Non-interventional study
• Data collection methods:
  Primary data collection

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Medicinal product name:
  ENHERTU
• Study drug International non-proprietary name (INN) or common name:
  TRASTUZUMAB DERUXTECAN
• Medical condition to be studied:
  Gastric cancer

Population studied

• Short description of the study population:
  Adult patients planned to be treated with T-DXd or conventional therapies for advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen

Study design details

• Study design:
  Multinational, multicenter, prospective observational, non-interventional study with trastuzumab deruxtecan in adult patients with advanced HER2-positive gastric or GEJ adenocarcinoma who have received a prior trastuzumab-based regimen in a real-world setting in Europe
• Main study objective:
  The primary objective is to describe the effectiveness of T-DXd based on real-world Time to Next Treatment (rwTTNT1) in adult patients with advanced HER2-positive gastric or GEJ adenocarcinoma who have received a prior trastuzumab-based regimen in a real-world setting.